Yahoo
NasdaqCM - Delayed Quote USD

Genelux Corporation (GNLX)

2.6300 -0.0700 (-2.59%)
At close: 4:00:01 PM EDT
2.6300 0.0000 (0.00%)
After hours: 4:58:19 PM EDT
Trade Genelux on Coinbase
Chart Range Bar
Loading chart for GNLX
  • Previous Close 2.7000
  • Open 2.7000
  • Bid 1.9600 x 200
  • Ask 3.3500 x 200
  • Day's Range 2.6100 - 2.7600
  • 52 Week Range 2.2900 - 8.5350
  • Volume 274,815
  • Avg. Volume 204,688
  • Market Cap (intraday) 117.93M
  • Beta (5Y Monthly) 0.59
  • PE Ratio (TTM) --
  • EPS (TTM) -0.8500
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 17.50

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

www.genelux.com

25

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/13/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GNLX
39.68%
S&P 500 (^GSPC)
13.93%

1-Year Return

GNLX
17.81%
S&P 500 (^GSPC)
20.60%

3-Year Return

GNLX
88.64%
S&P 500 (^GSPC)
74.71%

5-Year Return

GNLX
56.17%
S&P 500 (^GSPC)
74.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -8.93M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-8M
-6M
-4M
-2M
0

Analyst Insights

View More

Analyst Price Targets

10.00
17.50 Average
2.6300 Current
31.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/20/2026
Analyst Benchmark
Rating Action Maintains
Rating Speculative Buy
Price Action Lowers
Price Target 23 -> 20

Statistics

View More

Valuation Measures

Annual
As of 8/10/2026
  • Market Cap

    119.05M

  • Enterprise Value

    95.34M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    13.45k

  • Price/Book (mrq)

    5.33

  • Enterprise Value/Revenue

    12.31k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -60.56%

  • Return on Equity (ttm)

    -127.28%

  • Revenue (ttm)

    8k

  • Net Income Avi to Common (ttm)

    -33.58M

  • Diluted EPS (ttm)

    -0.8500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    26.21M

  • Total Debt/Equity (mrq)

    10.89%

  • Levered Free Cash Flow (ttm)

    -15.33M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.6300 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: